Research programme: bispecific antibody drug conjugates - ABL Bio/Beijing Biocytogen
Alternative Names: bsADCs - ABL Bio/Beijing BiocytogenLatest Information Update: 08 Apr 2024
At a glance
- Originator ABL Bio; Beijing Biocytogen
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer